Inclusion body myositis in the rheumatology clinic

Int J Rheum Dis. 2020 Aug;23(9):1126-1135. doi: 10.1111/1756-185X.13902. Epub 2020 Jul 14.

Abstract

Inclusion body myositis is a rare sporadic inflammatory-degenerative myopathy of the elderly. Despite being the commonest type of acquired myopathy after the age of 50, misdiagnosis is extremely common. The most frequent hurdle in identifying new cases is the wrong diagnosis of polymyositis or motor neuron disease. Novel insights into pathogenic mechanisms have heralded the quest for newer therapeutics as well as drug repurposing in this otherwise progressive disorder.

Keywords: clinical aspects; disease etiology and pathogenesis; drug treatment; human; myositis and related syndromes.

Publication types

  • Review

MeSH terms

  • Antirheumatic Agents / therapeutic use
  • Diagnosis, Differential
  • Diagnostic Errors
  • Disease Progression
  • Drug Repositioning
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Motor Neuron Disease / diagnosis*
  • Myositis, Inclusion Body / diagnosis*
  • Myositis, Inclusion Body / epidemiology
  • Myositis, Inclusion Body / therapy
  • Polymyositis / diagnosis*
  • Predictive Value of Tests
  • Prognosis
  • Rheumatology*
  • Risk Factors

Substances

  • Antirheumatic Agents
  • Immunosuppressive Agents